Apical Medium Flow Influences the Morphology and Physiology of Human Proximal Tubular Cells in a Microphysiological System.

cilia kidney micro-physiological systems microfluidics organ-on-chip

Journal

Bioengineering (Basel, Switzerland)
ISSN: 2306-5354
Titre abrégé: Bioengineering (Basel)
Pays: Switzerland
ID NLM: 101676056

Informations de publication

Date de publication:
30 Sep 2022
Historique:
received: 16 08 2022
accepted: 16 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

There is a lack of physiologically relevant in vitro human kidney models for disease modelling and detecting drug-induced effects given the limited choice of cells and difficulty implementing quasi-physiological culture conditions. We investigated the influence of fluid shear stress on primary human renal proximal tubule epithelial cells (RPTECs) cultured in the micro-physiological Vitrofluid device. This system houses cells seeded on semipermeable membranes and can be connected to a regulable pump that enables controlled, unidirectional flow. After 7 days in culture, RPTECs maintained physiological characteristics such as barrier integrity, protein uptake ability, and expression of specific transporters (e.g., aquaporin-1). Exposure to constant apical side flow did not cause cytotoxicity, cell detachment, or intracellular reactive oxygen species accumulation. However, unidirectional flow profoundly affected cell morphology and led to primary cilia lengthening and alignment in the flow direction. The dynamic conditions also reduced cell proliferation, altered plasma membrane leakiness, increased cytokine secretion, and repressed histone deacetylase 6 and kidney injury molecule 1 expression. Cells under flow also remained susceptible to colistin-induced toxicity. Collectively, the results suggest that dynamic culture conditions in the Vitrofluid system promote a more differentiated phenotype in primary human RPTECs and represent an improved in vitro kidney model.

Identifiants

pubmed: 36290484
pii: bioengineering9100516
doi: 10.3390/bioengineering9100516
pmc: PMC9598399
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Philip Morris International (Switzerland)
ID : Philip Morris International is the sole source of funding and sponsor of this research

Références

Int J Antimicrob Agents. 2016 Dec;48(6):592-597
pubmed: 27793510
Cell Cycle. 2011 Aug 15;10(16):2683-90
pubmed: 21814045
ALTEX. 2018 Dec 20;36(2):289-313
pubmed: 30570669
AAPS J. 2018 Jul 26;20(5):87
pubmed: 30051196
Pflugers Arch. 2017 Aug;469(7-8):877-887
pubmed: 28600680
Biochem Biophys Res Commun. 1999 Mar 5;256(1):240-8
pubmed: 10066454
Biomicrofluidics. 2016 Nov 16;10(6):064106
pubmed: 27917253
Drug Metab Dispos. 2018 Nov;46(11):1692-1702
pubmed: 30076203
J Pharm Sci. 2021 Apr;110(4):1601-1614
pubmed: 33545187
Sci Rep. 2021 Oct 29;11(1):21296
pubmed: 34716334
Methods Cell Biol. 2019;153:43-67
pubmed: 31395384
Environ Health Perspect. 1998 Apr;106 Suppl 2:559-69
pubmed: 9599703
J Physiol. 2021 Jul;599(14):3437-3446
pubmed: 34036593
Crit Care Med. 2008 Apr;36(4 Suppl):S216-23
pubmed: 18382197
Lab Chip. 2018 Dec 4;18(24):3814-3829
pubmed: 30460365
Kidney Int. 2020 Nov;98(5):1225-1241
pubmed: 32610050
Cytotechnology. 2016 Mar;68(2):179-96
pubmed: 25894791
Clin Pharmacol Ther. 2009 Oct;86(4):396-402
pubmed: 19625999
Pharm Res. 2007 Apr;24(4):811-5
pubmed: 17372702
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21860-5
pubmed: 21106755
Kidney Int. 2013 Apr;83(4):593-603
pubmed: 23389418
J Am Soc Nephrol. 2006 Jan;17(1):39-45
pubmed: 16319186
Int J Mol Sci. 2020 Jun 25;21(12):
pubmed: 32630605
Sci Rep. 2015 Aug 06;5:12917
pubmed: 26246421
Cell. 2007 Jun 29;129(7):1351-63
pubmed: 17604723
J Membr Biol. 2001 Nov 1;184(1):71-9
pubmed: 11687880
Micromachines (Basel). 2019 Aug 13;10(8):
pubmed: 31412604
J Am Soc Nephrol. 2017 Jun;28(6):1783-1791
pubmed: 28052987
Trends Biotechnol. 2016 Feb;34(2):156-170
pubmed: 26708346
Biochem Biophys Res Commun. 2017 Mar 4;484(2):358-364
pubmed: 28131833
ALTEX. 2020 Feb 28;37(3):365-394
pubmed: 32113184
Adv Biosyst. 2019 May;3(5):e1900018
pubmed: 32627410
Circ Res. 1996 Oct;79(4):834-9
pubmed: 8831508
Integr Biol (Camb). 2013 Sep;5(9):1119-29
pubmed: 23644926
Philos Trans R Soc Lond B Biol Sci. 2007 Aug 29;362(1484):1459-67
pubmed: 17569643
Am J Transl Res. 2019 Mar 15;11(3):1219-1229
pubmed: 30972157
ALTEX. 2016;33(3):272-321
pubmed: 27180100
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11418-23
pubmed: 18685100
Nat Rev Nephrol. 2017 Oct;13(10):629-646
pubmed: 28804120
Toxicol Appl Pharmacol. 2008 Dec 15;233(3):428-38
pubmed: 18930752
Eur J Clin Pharmacol. 2015 Jul;71(7):801-10
pubmed: 26008213
Chonnam Med J. 2018 May;54(2):83-89
pubmed: 29854673
J Am Soc Nephrol. 2010 Nov;21(11):1859-67
pubmed: 20798259
Trends Pharmacol Sci. 2016 Feb;37(2):114-119
pubmed: 26651415
AORN J. 1998 Nov;68(5):800, 803-16, 819-20; quiz 821-4
pubmed: 9829131
Semin Nephrol. 2019 Mar;39(2):215-226
pubmed: 30827343
Adv Biosyst. 2020 Nov;4(11):e2000079
pubmed: 33073544
J Cell Biol. 2000 Oct 30;151(3):709-18
pubmed: 11062270
Adv Drug Deliv Rev. 2017 Jul 1;116:73-91
pubmed: 28111348
PLoS One. 2015 Jul 06;10(7):e0131416
pubmed: 26146837
Int J Mol Sci. 2019 Oct 22;20(20):
pubmed: 31652595
Front Pharmacol. 2021 Dec 21;12:785851
pubmed: 35342386
Nat Rev Nephrol. 2018 Jun;14(6):378-393
pubmed: 29626199
Biotechnol Bioeng. 2010 Nov 1;107(4):707-16
pubmed: 20552673
Annu Rev Pharmacol Toxicol. 2013;53:503-29
pubmed: 23140242
ACS Infect Dis. 2015 Nov 13;1(11):568-575
pubmed: 27525307

Auteurs

Gabriele Specioso (G)

School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, 4132 Muttenz, Switzerland.

David Bovard (D)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Filippo Zanetti (F)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Fabio Maranzano (F)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Céline Merg (C)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Antonin Sandoz (A)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Bjoern Titz (B)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Federico Dalcanale (F)

School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, 4132 Muttenz, Switzerland.

Julia Hoeng (J)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Kasper Renggli (K)

Philip Morris International (PMI) R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchatel, Switzerland.

Laura Suter-Dick (L)

School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, 4132 Muttenz, Switzerland.
Swiss Centre for Applied Human Toxicology (SCAHT), 4056 Basel, Switzerland.

Classifications MeSH